OncoMatch/Clinical Trials/NCT06876662
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Is NCT06876662 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Pirtobrutinib for chronic lymphocytic leukemia.
Treatment: Pirtobrutinib — Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sylvester Comprehensive Cancer Center · Miami, Florida
- Florida Cancer Specialists · Sarasota, Florida
- The Emory Clinic · Atlanta, Georgia
- Northwestern University · Chicago, Illinois
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify